China-focused Mabtech licenses four mAB candidates to Sorrento

Mabtech, a holding company for China mAB biotechs, has in-licensed four monoclonal antibodies to San Diego-based Sorrento Therapeutics ($SRNE) with all of the candidates having completed Phase III trials in China, according to a press release. Two of the candidates have filed for marketing approval in China. The deal gives Sorrento, part of a web of biotechs affiliated to billionaire entrepreneur Patrick Soon-Shiong, rights in the U.S., Europe and Japan. Mabtech, owned by Asia-based private equity firm CDH Investments, or Sorrento, did not disclose financial or development details. Release